company background image
AT1

Atomo DiagnosticsASX:AT1 Stock Report

Market Cap

AU$204.7m

7D

0%

1Y

14.3%

Updated

24 Oct, 2021

Data

Company Financials +
AT1 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AT1 Overview

Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing in Australia and internationally.

Atomo Diagnostics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Atomo Diagnostics
Historical stock prices
Current Share PriceAU$0.36
52 Week HighAU$0.13
52 Week LowAU$0.37
Beta0
1 Month Change24.14%
3 Month Change80.00%
1 Year Change14.29%
3 Year Changen/a
5 Year Changen/a
Change since IPO-7.69%

Recent News & Updates

Jul 19
We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Feb 26
Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

Atomo Diagnostics Limited ( ASX:AT1 ) is possibly approaching a major achievement in its business, so we would like to...

Shareholder Returns

AT1AU Medical EquipmentAU Market
7D0%1.2%0.6%
1Y14.3%-7.6%21.3%

Return vs Industry: AT1 exceeded the Australian Medical Equipment industry which returned -7.6% over the past year.

Return vs Market: AT1 underperformed the Australian Market which returned 21.3% over the past year.

Price Volatility

Is AT1's price volatile compared to industry and market?
AT1 volatility
AT1 Beta0
Industry Beta0.57
Market Beta1

Stable Share Price: AT1 is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: AT1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2010n/aJohn Kellyhttps://atomodiagnostics.com

Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing in Australia and internationally. The company offers AtomoRapid RDT platforms to suit various blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases. Its rapid test devices are used by healthcare professionals and by consumers to screen for a range of diseases and medical conditions, including HIV infection.

Atomo Diagnostics Fundamentals Summary

How do Atomo Diagnostics's earnings and revenue compare to its market cap?
AT1 fundamental statistics
Market CapAU$204.70m
Earnings (TTM)-AU$6.02m
Revenue (TTM)AU$6.72m

30.5x

P/S Ratio

-34.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AT1 income statement (TTM)
RevenueAU$6.72m
Cost of RevenueAU$3.63m
Gross ProfitAU$3.09m
ExpensesAU$9.11m
Earnings-AU$6.02m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Oct 29, 2021

Earnings per share (EPS)-0.011
Gross Margin45.96%
Net Profit Margin-89.66%
Debt/Equity Ratio0%

How did AT1 perform over the long term?

See historical performance and comparison

Valuation

Is Atomo Diagnostics undervalued compared to its fair value and its price relative to the market?

31.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AT1 (A$0.36) is trading below our estimate of fair value (A$0.53)

Significantly Below Fair Value: AT1 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AT1 is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: AT1 is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AT1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AT1 is overvalued based on its PB Ratio (6.8x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Atomo Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

102.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AT1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: AT1 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AT1's is expected to become profitable in the next 3 years.

Revenue vs Market: AT1's revenue (36% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: AT1's revenue (36% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AT1 is forecast to be unprofitable in 3 years.


Past Performance

How has Atomo Diagnostics performed over the past 5 years?

-14.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AT1 is currently unprofitable.

Growing Profit Margin: AT1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AT1 is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare AT1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AT1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: AT1 has a negative Return on Equity (-20.01%), as it is currently unprofitable.


Financial Health

How is Atomo Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: AT1's short term assets (A$25.5M) exceed its short term liabilities (A$2.1M).

Long Term Liabilities: AT1's short term assets (A$25.5M) exceed its long term liabilities (A$23.1K).


Debt to Equity History and Analysis

Debt Level: AT1 is debt free.

Reducing Debt: AT1 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AT1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AT1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Atomo Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AT1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AT1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AT1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AT1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AT1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average board tenure


CEO

John Kelly

no data

Tenure

AU$467,301

Compensation

Mr. John Michael Kelly founded Atomo Diagnostics Ltd. in 2010 and serves as its Chief Executive Officer & Managing Director. Mr. Kelly has significant med-tech experience, having held senior operational an...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD349.15K) is below average for companies of similar size in the Australian market ($USD552.62K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: AT1's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Atomo Diagnostics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Atomo Diagnostics Limited
  • Ticker: AT1
  • Exchange: ASX
  • Founded: 2010
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$204.695m
  • Shares outstanding: 568.60m
  • Website: https://atomodiagnostics.com

Location

  • Atomo Diagnostics Limited
  • 701-703 Parramatta Road
  • Level 2
  • Leichhardt
  • New South Wales
  • 2040
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/24 07:02
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.